Access & Support

ForgingBridges® is committed to
providing continuous support

Program Overview
Access Resources

Actor portrayals.

Program Overview icon

ForgingBridges is a personalized support program,
providing you
and your patients with:

chat

A dedicated team
to support you, your
office staff, and your
patients through the
treatment journey

A dedicated team to support you, your office staff, and your patients through the treatment journey

  • Field Reimbursement Managers (FRMs) for healthcare providers and office staff
  • Patient Access Liaisons (PALs) for patients and their caregivers
  • ForgingBridges Specialists for personalized coverage support and financial assistance options
list

Insurance navigation

Insurance navigation

Regardless of insurance type, our dedicated ForgingBridges support team will help ensure all necessary information has been collected, evaluate patients' eligibility, and initiate next steps.

list

ForgingBridges Copay Assistance Program

ForgingBridges Copay Assistance Program

Reduce out-of-pocket costs (including copays, coinsurance, or deductibles) to as little as $0 per month for Attruby for eligible, commercially insured patients.

Commercially insured patients only. Additional terms and conditions may apply

lightbulb

Nationally, more than 90% of Medicare Part D patients have access to Attruby with final coverage decision†

Once prescribed Attruby, patients or their caregivers can connect with ForgingBridges
Specialists who can screen their eligibility for financial assistance programs.

Questions? Call ForgingBridges at
1-888-55-BRIDGE (1-888-552-7434)
Mon–Fri, 8 AM to 8 PM ET or visit
ForgingBridges.com

lightbulb

Nationally, more than 90% of Medicare Part D patients have access to Attruby with final coverage decision†

drugs

ForgingBridges
Free Trial

ForgingBridges Free Trial

Provides eligible patients with a 1-month supply of Attruby.*

New Attruby patients with any
insurance coverage

man

ForgingBridges Patient Assistance Program

ForgingBridges Patient Assistance Program

May provide eligible patients with Attruby
at no cost.

Patients must meet certain income criteria and be either currently uninsured or have limited coverage, or have received an appeal denial

heart pill

ForgingBridges QuickStart

ForgingBridges QuickStart

Provides a limited supply of Attruby at no cost for eligible patients experiencing coverage decision delays.

Patients with any insurance type

*For eligibility criteria and terms and conditions, call ForgingBridges at 1-888-55-BRIDGE (1-888-552-7434) or visit ForgingBridges.com.

†As of August 15, 2025.

logo

Questions?

Call ForgingBridges at:
1-888-55-BRIDGE
(1-888-552-7434)
Mon–Fri, 8 AM to 8 PM ET

Additional information on
the
services offered by ForgingBridges is
available
at ForgingBridges.com.

Program Overview
Access Resources
Program Overview icon

HCP ForgingBridges Support Video

hospital

See the helpful resources available to you, your staff,
and your patients

See Resources

Indication and Important safety information

INDICATION

Attruby® (acoramidis) is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION

Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation.

Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

Laboratory Tests
Mean increase in serum creatinine of 0.2 and 0.0 mg/dL and a mean decrease in eGFR of 8.2 and 0.7 mL/min/1.73 m2 was observed in the adults with ATTR-CM treated with Attruby versus placebo, respectively, at Day 28 and then stabilized. These changes were reversible after treatment discontinuation.

Use in Specific Populations

Pregnancy & Lactation: There are no data on the use of Attruby in pregnant women. Animal data have not shown developmental risk associated with the use of Attruby in pregnancy. There are no available data on the presence of Attruby in either human or animal milk or the effects of the drug on the breastfed infant or maternal milk production.

Please see Full Prescribing Information including Patient Information.

INDICATION AND IMPORTANT
SAFETY INFORMATION

INDICATION

Attruby® (acoramidis) is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION

Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation.

Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

Laboratory Tests
Mean increase in serum creatinine of 0.2 and 0.0 mg/dL and a mean decrease in eGFR of 8.2 and 0.7 mL/min/1.73 m2 was observed in the adults with ATTR-CM treated with Attruby versus placebo, respectively, at Day 28 and then stabilized. These changes were reversible after treatment discontinuation.

Use in Specific Populations

Pregnancy & Lactation: There are no data on the use of Attruby in pregnant women. Animal data have not shown developmental risk associated with the use of Attruby in pregnancy. There are no available data on the presence of Attruby in either human or animal milk or the effects of the drug on the breastfed infant or maternal milk production.

Please see Full Prescribing Information including Patient Information.